Early results from Blue Lake trial found the vaccine to be safe, tolerated and able to cut the chance of contracting the infection.

The Phase III study saw the drug able to cut risk of death by 38% with imlunestrant alone, and down so far as 43% with Verzenio.

Enlivex has gained approval from the Israeli regulator approval to commence a Phase I trial of Allocetra in people with TMJ osteoarthritis.

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.